Global Breast Cancer Treatment Market Report and Forecast 2024-2032

Global Breast Cancer Treatment Market Outlook

The global breast cancer treatment market size attained a value of USD 22.49 billion in 2023. The market is likely to grow at a rate of 10.10% during the forecast period of 2024-2032. The market growth is driven by the growing demand for diagnostics and therapeutics and the market is anticipated to be worth USD 53.47 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Breast Cancer: Types, Causes, Diagnosis, and Treatment

Breast cancer is the abnormal cell growth in and around the breast region. Breast cancer is of several types, depending on the breast cells that are converted into cancerous ones. Most of the breast cancers begin in the ducts or lobules of the breast and then eventually spread to the other surrounding regions. 

The two most common types of breast cancer are invasive ductal carcinoma and invasive lobular carcinoma. The breast cancer is classified as metastasized when it spread outside to the other parts of the body. The common clinical manifestations of breast cancer include formation of new lumps, breast thickening, skin irritation, redness in the nipple area, and pain in the breast area.

The diagnosis of breast cancer can be performed with the help of additional tests including breast ultrasound, diagnostic mammogram, breast magnetic resonance imaging, and biopsy. The precise and accurate diagnosis is essential to determine the cancer staging, in order to provide the related treatment and management.

There are different treatment regimens for the eradication of breast cancer. This includes surgery, chemotherapy, hormonal therapy, biological therapy, and radiation therapy. These therapeutic interventions will aid in removing the cancerous lumps and controlling the spreadability of cancerous cells to the other organs. 

The breast cancer treatment market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Therapy

• Targeted Therapy
  • Abemaciclib
  • Ado-Trastuzumab Emtansine
  • Everolimus
  • Trastuzumab
  • Ribociclib
  • Palbociclib
  • Pertuzumab
  • Olaparib
  • Others
• Hormonal Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Aromatase Inhibitors
  • Estrogen Receptor Downregulators (ERDs)
• Chemotherapy

• Immunotherapy

• Others

Breast Cancer Treatment Market Breakup by Indication

• Invasive Ductal Carcinoma

• Invasive Lobular Carcinoma

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Others

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The growth of the breast cancer treatment market is driven by the increasing prevalence and incidence of breast cancer in both developing and developed nations. According to the Cancer Australia, in 2021, the risk of breast cancer was estimated to be 1 in 15 individuals by the age of 85. Thus, the rising cases of breast cancer has directly influenced the demand for the breast cancer treatment, thereby attributing to the market growth.

The growing research and development activities by the strategic key market players are expected to accelerate the launch and development of novel therapeutic products, that will further boost the market during the forecast period. For example, in September 2021, Novartis collaborated with the SOLTI Innovative Cancer Research for performing the clinical trials for a novel therapy that has shown some promising effects for the treatment of the metastatic breast cancer with a HER2E intrinsic subtype.

The rising number of mergers and acquisitions among the major pharmaceutical companies is also expected to bolster the breast cancer treatment market growth. Recently, Pfizer and Arvinas have collaborated to develop and commercialise ARV-471, an investigational therapy, that has been effective in the management of the breast cancer.

Key Market Trends by Therapy and Region

Among the therapies, chemotherapy is anticipated to hold the maximum share in the breast cancer treatment market owing to the growing patient pool receiving chemotherapy and the novel product launches and approvals in this sector. According to the Centres for Disease Control and Prevention, nearly 650,000 patients receive chemotherapy annually in the United States. 

North America is expected to dominate the market during the forthcoming period due to the increasing disease burden and raising awareness in this region. According to breastcancer.org, nearly, one in eight women develop invasive breast cancer over their lifetime in the United States. Further, the expanding research activities and advanced healthcare facilities in the region are expected to propel the breast cancer treatment market growth during the forecast period.

Therapeutic Landscape

The treatment of the breast cancer depends on the type of breast cancer, its stage, size, and the extent of spreadability in the body. The therapeutic interventions incorporate the different types of surgeries, medications, and other supporting palliative care.

Different Therapies: Radiotherapy, Chemotherapy, Immunotherapy, and Targeted Drug Therapies

The commonly used method is the surgical procedure which involves the removing of the tumour, lymph nodes, entire breast, or both breasts. The different invasive procedures used in the eradication of the breast tumours are lumpectomy, mastectomy, sentinel node biopsy, and axillary lymph node dissection.

Radiation therapy is utilised for the killing of the cancerous cells with the help of the high-powered beams of energy, such as protons and X-rays. The breast radiation therapy is generally done after the surgical interventions to kill the left-over cancerous cells if any, and usually lasts for three days to six weeks depending on the treatment scenario.

Chemotherapy is another therapy which is applied for destroying the fast-growing cancerous cells with the help of the drugs. This therapy is considered after surgery to prevent the risks of recurrence of cancer and to control the spreadability of the cancer.

Hormone therapy is incorporated in the cases, where the cancers are hormone sensitive, and are referred to as progesterone receptor positive and oestrogen receptor positive. This type of therapy can be used before or after the surgery to control and reduce the size of cancer.

Along with all the available treatment strategies, palliative care should be provided to improve the quality of life and increase the longevity of the patient.

Clinical Trials Landscape of the Breast Cancer Treatment Market

The recent discovery of novel targeted therapies has been of major interest to experts, researchers, and key players. Tremendous efforts and intensive research and development are under process for immunotherapy and tyrosine kinase inhibitors. Despite the discovery of many novel oncological agents, the focus of the scientists is to explore the optimisation of new therapeutic interventions into clinical practice.

Scientists at Tel Aviv University are developing a novel treatment, that is expected to increase the efficacy of chemotherapy in the breast cancer patients. The therapy produces a cancer promoting inflammatory environment in response to the chemotherapy, and thus, with the addition of anti-inflammatory agent, metastasis can be prevented.

An experimental breast cancer vaccine has shown promising effects in the treatment of the advanced stage ERBB2-positive breast cancer. Currently, the vaccine is under the advanced phases of clinical trials and target the receptor in the breast cancer.

Researchers from the University of Amazonia are performing the clinical trials in the animal and human models for treating the triple negative breast cancer. The drug is based on the epidermal growth factor receptor technology and is presently under Phase I clinical trials.

The significant advancements have led to the discovery of many novel therapeutic products, which are anticipated to bolster the market growth and development, once approved.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the breast cancer treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Mylan N.V (Viatris Inc.)

• AstraZeneca
   
• Celltrion Inc.

• Bristol-Myers Squibb Company

• Fresenius Kabi AG

• Eisai Co., Ltd.

• Baxter

• GSK plc

• Pfizer Inc. 

• Halozyme, Inc. 

• Novartis AG

Key Highlights of the Report

Breast Cancer Treatment  Drugs Market Report Snapshots

Breast Cancer Treatment  Drugs Market Size

Breast Cancer Treatment  Drugs Companies